Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis
Open Access
- 15 January 2019
- journal article
- research article
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 13 (1), 83-92
- https://doi.org/10.5009/gnl17569
Abstract
Background/Aims: Lysyl oxidase-like 2 (LOXL2), a collagen-modifying enzyme, has been implicated in cancer invasiveness and metastasis. Methods: We evaluated the expression of LOXL2 protein, in addition to carbonic anhydrase IX (CAIX), keratin 19, epithelial cell adhesion molecule, and interleukin 6, in 105 resected hepatocellular carcinomas (HCCs) by immunohistochemistry. Results: LOXL2 positivity was found in 14.3% (15/105) of HCCs, and it was significantly associated with high serum alpha-fetoprotein levels, poor differentiation, fibrous stroma, portal vein invasion, and advanced TNM stage (p<0.05 for all). Additionally, LOXL2 positivity was significantly associated with CAIX (p=0.005) and stromal interleukin 6 expression (p=0.001). Survival analysis of 99 HCC patients revealed LOXL2 positivity to be a poor prognostic factor; its prognostic impact appeared in progressed HCCs. Furthermore, LOXL2 positivity was shown to be an independent predictor of overall survival and disease-specific survival (p<0.05 for all). Interestingly, co-expression of LOXL2 and CAIX was also an independent predictor for overall survival, disease-specific survival, disease-free survival, and extrahepatic recurrence-free survival (p<0.05 for all). Conclusions: LOXL2 expression represents a subgroup of HCCs with more aggressive behavior and is suggested to be a poor prognostic marker in HCC patients.Keywords
This publication has 39 references indexed in Scilit:
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2016
- A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016Clinical and Molecular Hepatology, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- The extracellular matrix: A dynamic niche in cancer progressionThe Journal of cell biology, 2012
- Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosisJournal of Hepatology, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancerDisease Models & Mechanisms, 2011
- Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cellsJournal of Hepatology, 2010
- Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin SignalingCell, 2009
- A tense situation: forcing tumour progressionNature Reviews Cancer, 2009